IRB #

STUDY00020400

Title

[MOU - NMDP IRB] An Open-Label, Single-Arm, Multicenter Study, of Combination anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease

Principal Investigator

Gabrielle Meyers

Study Purpose

We are doing this study to see if T-Guard works to treat acute GVHD that doesn't get better with steroids. We want to know if T-Guard therapy will make your acute GVHD go away completely after 28 days.

Medical Condition(s)

Acute GVHD
aGVHD
Acute Graft Versus Host Disease
Steroid Refractory
Allogeneic stem cell transplant

Eligibility Criteria

- 12 years or older.
- Previous allogeneic stem cell transplant using bone marrow, peripheral blood stem cells or cord blood.
Steroid refractory acute GVHD after allogeneic transplant.
- Prior treatment with steroids

Age Range

12 - 120

Healthy Volunteers Needed

No

Duration of Participation

180 days

Minors Included

Yes

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

National Institute of Health
National Heart, Lung and Blood Institute
National Cancer Institute
Xenikos BV

Recruitment End

01/01/2025

Compensation Provided

No


Go Back